Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Corcept Therapeutics (CORT)

Corcept stockholders approve 2024 Incentive Award Plan with 8,000,000 new shares

Neutral Impact 2 of 5 shareholder Written later

At its May 17, 2024 annual meeting, Corcept's stockholders approved the 2024 Incentive Award Plan, which replaces the 2012 Plan. The filing also reports the election of nine directors, the ratification of Ernst & Young LLP as auditor for 2024, and an advisory approval of executive compensation. The new plan sets the share pool for equity awards going forward.

Key points

  • The 2024 Plan reserves 8,000,000 shares, plus 4,073,955 shares available under the 2012 Plan as of May 17, 2024, plus any shares from lapsed 2012 Plan awards.
  • Plan approval vote: 47,018,093 for, 18,698,799 against, 161,233 abstentions, with 22,496,239 broker non-votes.
  • All nine director nominees were elected to serve until the 2025 annual meeting.
  • Stockholders ratified Ernst & Young LLP for the fiscal year ending December 31, 2024, with 86,596,528 votes for and 1,707,066 against.

The filing

CompanyCorcept Therapeutics (CORT)
Form8-K, current report
Filed with the SECMay 23, 2024, 4:11 PM ET
Accession number0001628280-24-024936

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 23, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.